Matthias König: Developing an Open Whole-Body PBPK/PD Digital Twin of Apixaban
Matthias König, Associate Professor of Pharmacoepidemiology and Data Science at University of Southern Denmark, shared a post on LinkedIn about a recent preprint, he and his colleagues co-authored, published in Preprints.org, adding:
“New preprint: ‘An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics.’
In this work, we developed an open whole-body PBPK/PD digital twin of the direct oral anticoagulant apixaban, linking drug exposure to anticoagulation-related pharmacodynamic endpoints, including INR, PT, mPT, aPTT, and anti-Xa activity.
The model was built and evaluated using data from 35 curated clinical PK/PD studies, covering diverse dosing regimens and clinically relevant scenarios, including renal and hepatic impairment, food intake, and body weight effects.
It captures apixaban pharmacokinetics and pharmacodynamics across these populations and provides a reusable framework for personalised anticoagulant therapy.
A key focus was reproducibility and openness: all models, simulation workflows, documentation, and curated datasets are openly available and FAIR-compliant, enabling transparent reuse, independent verification, and future extension.
The work was developed as part of the Berlin University Alliance (BUA) X-Student Research Group ‘Digital Twins in Action:
Optimizing Direct Oral Anticoagulant Use’, funded by the Bundesministerium für Bildung und Forschung (BMBF) and the State of Berlin as part of the Excellence Strategy of the Federal and State Governments.”
Title: An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics
Authors: Mariia Myshkina, Mariia Babaeva, Linh Chang Nguyen, Shelee Bedón, Johannes Metternich, Michelle Elias, Matthias König
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering